Homing Post Injury - ExoPTEN
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06 sept. 2024 16h03 HE | NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
2024_Process Robustness
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
15 août 2024 16h03 HE | NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
Electroretinogram (ERG) measurements
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
17 juil. 2024 16h14 HE | NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
Optic Nerve Regeneration - research team
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28 juin 2024 16h04 HE | NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
Alterity.png
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
08 mai 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
 - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
Alterity.png
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
29 avr. 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
Alterity.png
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17 avr. 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Alterity.png
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
10 avr. 2024 07h25 HE | ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity.png
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
26 mars 2024 10h25 HE | ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company...
Alterity.png
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20 févr. 2024 10h25 HE | ALTERITY THERAPEUTICS LIMITED
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...